Statement of Cash Flows-indirect Meth The comparative balance sheet of Livers Inc. for December 31, 2043 and 20Y2, is shown as follows: Dec. 31, 20Y3 Dec. 31, 20Y2 Assets Cash $296,310 $276,590 Accounts receivable (net) 107,340 303,020 Inventories 99,340 294,110 113.950 Investments Land 155,420 0 Equipment Accumulated depreciation-equipment 334,320 (78,270) 260,030 (70,120) Total assets $1,118,140 $973,900 $191,860 Liabilities and Stockholders' Equity Accounts payable (merchandise creditors) Accrued expenses payable (operating expenses) Dividends payable Common stock, $10 par $ 202,380 20,130 25,320 11,180 8,770 60,380 47,720 Paid-in capital: Excess of issue price over par-common stock 226,980 132,450 Retained earnings 597,090 567,780 Total liabilities and stockholders' equity $1,118,140 $973,900 Additional data obtained from an examination of the accounts in the ledger for 20Y3 are as follows: a. The investments were sold for $133,320 cash. b. Equipment and land were acquired for cash. c. There were no disposals of equipment during the year. d. The common stock was issued for cash. e. There was a $75,000 credit to retained Earnings for net income. 1. There was a $45,770 debit to Retained Earnings for cash dividends declared. Required: Prepare a statement of cash flows, using the indirect method of presenting cash flows from operating activities. Use the minus sign to indicate cash out flows, cash payments, decreases in cash, or any negative adjustments Livers Inc. Statement of Cash Flows For the Year Ended December 31, 2023 Cash flows from operating activities Adjustments to reconcile net income to net cash flow from operating activities: Changes in current operating assets and liabilities: Q v 1100 do I Net cash flow from operating activities Cash flows from investing activities: o Net cash flow used for investing activities Cash flows from financing activities: Net cash flow from financing activities Cash at the beginning of the year Cash at the end of the year